Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxych...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases Vol. 21; no. 1; p. 72
Main Authors: Ip, Andrew, Ahn, Jaeil, Zhou, Yizhao, Goy, Andre H, Hansen, Eric, Pecora, Andrew L, Sinclaire, Brittany A, Bednarz, Urszula, Marafelias, Michael, Sawczuk, Ihor S, Underwood, 3rd, Joseph P, Walker, David M, Prasad, Rajiv, Sweeney, Robert L, Ponce, Marie G, La Capra, Samuel, Cunningham, Frank J, Calise, Arthur G, Pulver, Bradley L, Ruocco, Dominic, Mojares, Greggory E, Eagan, Michael P, Ziontz, Kristy L, Mastrokyriakos, Paul, Goldberg, Stuart L
Format: Journal Article
Language:English
Published: England BioMed Central Ltd 14-01-2021
BioMed Central
BMC
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-021-05773-w